You are here

OTHER FUNCTIONS - EFFICACY OF ORAL AMINOGLYCOSIDE-COCHLEATE FORMULATIONS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N44AI120021
Agency Tracking Number: N44AI120021
Amount: $744,075.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: N/A
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
COORDINATED PROGRAM DEVELOPMENT, LLC
FLEMINGTON, NJ 08822-4504
United States
DUNS: 832953678
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 SUSAN BONITZ
 (908) 256-2915
 SGBONITZ@GMAIL.COM
Business Contact
 SUSAN BONITZ
Phone: (908) 256-2915
Email: SGBONITZ@GMAIL.COM
Research Institution
 Stub
Abstract

Aminoglycosides are an important class of antibiotics for the treatment of aerobic, gram-negative bacteria (Pseudomonas, Acinetobacter, Enterobacter) and mycobacteria (Mycobacterium tuberculosis, M. avium), causes of serious co-infections in HIV-infected persons. Widespread use of aminoglycosides has been limited due to their toxicity (nephrotoxicity and ototoxicity) and inconvenient route of administration (intravenous or intramuscular); the adverse effects are related to plasma drug levels. For example, use of amikacin for first-line therapy is limited due to poor oral absorption, a short half-life, and serious renal and auditory toxicities which necessitate frequent intravenous administration, with concomitant monitoring of drug levels to ensure that thelevels in plasma remain within a narrow therapeutic window.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government